Jubilant Generics Limited

Jubilant Draximage Inc.

Jubilant Pharma Holdings Inc.

Indranil Nandi

Dinesh Kumar

Saurabh Srivastava

Tusharmouli Mukherjee

Rakesh K Singh

Kamal Surendrakumar Mehta

Amit Jha

Rajendra Shekhawat

James A Kaufman

Dominic Siewko

Rajesh Kumar

Ganesh Vinayak Gat

Dharam Vir

Robert A deKemp

Sujay Biswas

Michael Gertsenchtein

Dinesh Kumar Sarwal

Anil Jain

Gholamreza Mirshekari

Rohit Chakravarthy

Sanjeev Kumar

Chetan Balubhai Patel

Brijesh Kumar Shukla

Saji Thomas

Anilkumar Haribhat Lingabhat

Nirmal Kumar

Mohan Chikmagalur Sadashivappa

Tanima Ghosh

Steve Mupenda

Bidyut Biswas

Chadi Baida

Nagabasayya R Chikkamath

Chad Roger Ronald Nicholas Hunter

M Umamaheshwar Prasad

Eric James Moulton

The present invention relates to a medical radioisotope transport system that securely holds the radiopharmaceutical imaging system or medical elution system to the floor of a vehicle and ensures the protection of the elution system during transportation. The transport system as per the present invention includes at least a floor-mounting device, a support mechanism with transportation plates, and a locking device. The transport system as per the present invention is encompassed with advanced technical and safety features to ensure safe transportation of radiopharmaceuticals ensuring compliance to the regulatory and quality requirements. The transport system as per the present invention is easy to use, and successfully overcome all the complexities involved in prior available methods for transportation of radiopharmaceutical imaging systems or medical radioisotope elution systems.

Device to facilitate safe transport of medical radioisotope systems

The present invention relates to a theranostic delivery system or radiopharmaceutical drugs delivery system () with movable ergonomic workstation () having handles on the side(s) to move the cart. The radiopharmaceutical drugs delivery system () comprises of simple design and multiple enhanced safety features for user. The delivery system () includes a disposable secondary containment system () that protect the core workstation from contamination, a configurable dose transporter () that allows for safe transport of the hot dose between the hot lab to the infusion site and a disposable sealed fluid cartridge () to withdraw custom volume from the vial or syringe. The delivery system () comprises a theranostic informatics management system with a computer screen () as graphical user interface (GUI) with retractable rotating arm () to receive the various patient infusion parameters and effectively manage delivery of desired dose to patient.

Radiopharmaceutical delivery system for patient infusion

The present invention provides an image processing method to assess quantitative myocardial blood flow and/or myocardial flow reserve, comprising the steps of: (a) pre-processing of images comprises: (i) reconstructing dynamic cine 3D tomographic myocardial perfusion imaging (MPI) data, (ii) optionally, denoising to improve the quality of image, (iii) extracting blood input function from a region of interest (ROI) of the left ventricle blood cavity, (iv) estimating the distribution volume (DV), given by the ratio of uptake and washout rates (K/k) to stabilize and improve estimation of K, kand total blood volume (TBV) and subsequent myocardial blood flow measures, and (v) data normalization by dividing by the maximum of the blood input function; (b) assessing the individual signals pre-processed in step (a) in order to generate Kand TBV parametric maps using artificial neural network; (c) post-processing of K, kand TBV parametric maps; and of rest and stress myocardial blood flow to estimate myocardial flow reserve (MFR) and/or coronary flow reserve (CFR).

Imaging method for diagnosing cardiovascular disease

The invention is a theranostic delivery system or radiopharmaceutical drugs delivery system with movable workstation having handles. The workstation of theranostic delivery system or radiopharmaceutical drugs delivery system also has an on-board shielded disposal system for waste collection, which is operated by foot actuated system for locked and unlocked modes during the device journey. The theranostic delivery system or radiopharmaceutical drugs delivery system comprises a status light system that illuminates the working area to enable distance monitoring. Further, the delivery system includes a disposable secondary containment system that protects the core workstation from contamination, a configurable dose transporter and a disposable sealed fluid cartridge to withdraw custom volume from the vial or syringe. The delivery system includes a theranostic informatics management system, which contains a computer screen as a graphical user interface with a retractable rotating arm to receive the various patient infusion parameters.

Radiopharmaceutical delivery system and use thereof for patient infusion

The present invention relates to orally administered liquid pharmaceutical compositions of eslicarbazepine. The liquid compositions are in the form of ready to use suspension and suspension powder for reconstitution. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile and pH. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide physician with providing a more convenient and less cumbersome posology.

Eslicarbazepine suspension

Provided herein are the long-acting injection compositions of &#x3b2;3 adrenoreceptor agonists like mirabegron or their pharmaceutically acceptable salts or esters thereof. The present invention also relates to methods for preparing long-acting injection compositions and methods of using these dosage forms for the treatment of obesity, metabolic diseases, and other diseases as described herein. The long-acting injection compositions as per the present invention have desirable pharmaceutical technical attributes.

Long-acting injection dosage form of beta 3 adrenoreceptor agonists

The present invention discloses an extended release oral liquid pharmaceutical composition comprising eslicarbazepine or its pharmaceutically acceptable esters, salts, solvates, polymorphs, enantiomers or mixtures thereof in a pharmaceutically acceptable carrier. The extended release liquid compositions are in the form of ready-to-use liquid compositions or reconstituted liquid compositions. It also relates to processes for the preparation of said extended release liquid compositions. The prior art discloses immediate release oral liquid dosage form. The prepared novel test formulations exhibited desired pharmaceutical technical attributes.

Modified release suspension of eslicarbazepine

The present invention relates to a process for the preparation of angiotensin receptor blockers or its pharmaceutically acceptable salts thereof containing less than 10 ppm of the azido impurities. More particularly, the present invention relates to process for the preparation of Losartan, Losartan potassium of Formula I or its other pharmaceutically acceptable salts thereof containing less than 10 ppm of each of the azido impurities, wherein the azido impurity is selected from the group comprising of 5-(4'-(azidomethyl)-[1,1&#x2032;-biphenyl]-2-yl)-1H-tetrazole, 4&#x2032;-(azidomethyl)-[1,1&#x2032;-biphenyl]-2-carbonitrile, 4&#x2032;-((5-(azidomethyl)-2-butyl-4-chloro-1H-imidazol-1-yl)methyl)-[1,1&#x2032;-biphenyl]-2-carbonitrile, 5-(4&#x2032;-((5-(azidomethyl)-2-butyl-4-chloro-1H-imidazol-1-yl)methyl)-[1,1&#x2032;-biphenyl]-2-yl)-1H-tetrazole, 5-(azidomethyl)-2-butyl-4-chloro-1H-imidazole, 4&#x2032;-((4-(azidomethyl)-2-butyl-5-chloro-1H-imidazol-1-yl)methyl)-[1,1&#x2032;-biphenyl]-2-carbonitrile, 5-(4&#x2032;-((4-(azidomethyl)-2-butyl-5-chloro-1H-imidazol-1-yl)methyl)-[1,1&#x2032;-biphenyl]-2-yl)-1H-tetrazole and 1-((1-((2&#x2032;-(1H-tetrazol-5-yl)-[1,1&#x2032;-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methyl)-5-(4&#x2032;-((5-(azidomethyl)-2-butyl-4-chloro-1H-imidazol-1-yl)methyl)-[1,1&#x2032;-biphenyl]-2-yl)-1H-tetrazole. More particularly, the present invention relates to a simple, economical and industrially efficient process for the preparation of Losartan potassium of Formula I. 

Preparation of angiotensin receptor blockers or pharmaceutically acceptable salts thereof

The present invention relates to oral ready to use liquid pharmaceutical compositions of eslicarbazepine. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile, viscosity, pH, stability, and acceptable organoleptic properties. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide the physician with providing a more convenient and less cumbersome posology.

Disclosed are the injection compositions of &#x3b2;3 adrenoreceptor agonists such as mirabegron or their pharmaceutically acceptable salts or solvates or esters thereof. The present invention also relates to methods for preparing injection compositions and methods of using these dosage forms for the treatment of obesity, other related metabolic diseases, and reduction/removal of fat. The injection compositions as per the present invention have advantages of simple preparation, simple and convenient application, easy absorption, and better effect of treating. The compositions can also be used in cases where oral administration of the drug is not possible due to underlying conditions or concerns around inadequate oral absorption. The injection compositions as per the present invention have desirable pharmaceutical technical attributes.

Parenteral dosage form of &#x3b2;3 adrenoreceptor agonists

Disclosed herein are the sublingual pharmaceutical compositions comprising remdesivir or its pharmaceutically acceptable salts or solvates thereof. The present invention also relates to a process for preparing sublingual pharmaceutical compositions comprising remdesivir or its pharmaceutically acceptable salts or solvates thereof. Compositions of remdesivir prepared as per present invention are able to increase bioavailability by avoiding first-pass metabolism. The compositions of remdesivir prepared as per present invention are useful in the treatment of viral infections including coronavirus infection (COVID-19). The compositions of remdesivir prepared as per present invention exhibit desired pharmaceutical technical attributes such as pH, assay, related substance, disintegration and dissolution.

Transmucosal dosage forms of remdesivir

The invention relates to a commercially viable, cost effective and energy efficient process for the preparation of 2-(1H-Imidazol-4-yl)ethanamine or pharmaceutically acceptable salts thereof in high purity and yield via application of continuous flow technology.

Continuous process for the preparation of 2-(1H-imidazol-4-yl) ethanamine and pharmaceutically acceptable salts thereof

Growing community of inventors

Yardley, PA, United States of America

Indranil Nandi